1. Unbalanced expression of sICOS and sPD‐1 correlates with tumor progression in gastric cancer
   Cecília A. C. Lima et al, 2022, Journal of Surgical Oncology CrossRef
2. Serum‐soluble PD‐L1 may be a potential diagnostic biomarker in sepsis
   Shaoqiong Sun et al, 2021, Scandinavian Journal of Immunology CrossRef
3. Soluble Programmed Cell Death 1 Protein Is a Promising Biomarker to Predict Severe Liver Inflammation in Chronic Hepatitis B Patients
   Mingrong Ou et al, 2024, ACS Omega CrossRef
4. Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued
   Guichan Liao et al, 2022, Infection and Drug Resistance CrossRef
5. Aberrant production of soluble inducible T cell co-stimulator and soluble programmed cell death protein 1 in patients with chronic hepatitis B
   Dongsheng Wang et al, 2017, Molecular Medicine Reports CrossRef
6. Programmed death ligand 2 – A link between inflammation and bone loss in rheumatoid arthritis
   Stinne R. Greisen et al, 2020, Journal of Translational Autoimmunity CrossRef
7. Soluble (PD-1) and Autophagy protein (ATG-5) in patients with tuberculosis
   Suhaib Waad Oklah Musa et al, 2022, Bionatura CrossRef
8. Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma
   Minh Phuong Dong et al, 2020, Scientific Reports CrossRef
9. T-Cell Exhaustion in HIV-1/Hepatitis C Virus Coinfection Is Reduced After Successful Treatment of Chronic Hepatitis C
   Kamila Caraballo Cortés et al, 2023, Open Forum Infectious Diseases CrossRef
10. Soluble immune checkpoints in cancer: production, function and biological significance
    Daqian Gu et al, 2018, Journal for ImmunoTherapy of Cancer CrossRef
11. The PD-1/PD-Ls pathway and autoimmune diseases
    Suya Dai et al, 2014, Cellular Immunology CrossRef
12. Serum sPD‐L1, Upregulated in Sepsis, May Reflect Disease Severity and Clinical Outcomes in Septic Patients
    M. Liu et al, 2017, Scandinavian Journal of Immunology CrossRef
13. Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis
    Takemichi Fukasawa et al, 2017, Arthritis & Rheumatology CrossRef
14. Role of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients with cystic echinococcosis
    YANHUA LI et al, 2016, Experimental and Therapeutic Medicine CrossRef
15. Diagnostic value of soluble programmed cell death protein-1 in type-1 autoimmune hepatitis in Egyptian children
    Ola G. Behairy et al, 2020, Scandinavian Journal of Clinical and Laboratory Investigation CrossRef
16. Circulating level of sPD-1 and PD-1 genetic variants are associated with hepatitis B infection and related liver disease progression
    Pham Thi Minh Huyen et al, 2022, International Journal of Infectious Diseases CrossRef
17. Orthogonal quantification of soluble inducible T-cell costimulator (ICOS) in healthy and diseased human serum
    Kevin McKinski et al, 2022, Journal of Pharmaceutical Analysis CrossRef
18. Inducible T‐cell co‐stimulator (ICOS) and ICOS ligand are novel players in the multiple‐myeloma microenvironment
    Elena Boggio et al, 2022, British Journal of Haematology CrossRef
19. Serum soluble programmed cell death 1 levels predict spontaneous functional cure in inactive carriers with chronic hepatitis B
    Hui‐Han Hu et al, 2022, Alimentary Pharmacology & Therapeutics CrossRef
20. LncRNA XLOC_003810 promotes T cell activation and inhibits PD‐1/PD‐L1 expression in patients with myasthenia gravis‐related thymoma
    Bo Hu et al, 2020, Scandinavian Journal of Immunology CrossRef